-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Downgrades Verve Therapeutics to Hold, Lowers Price Target to $13

Benzinga·06/17/2025 14:34:04
Listen to the news
Canaccord Genuity analyst Whitney Ijem downgrades Verve Therapeutics (NASDAQ:VERV) from Buy to Hold and lowers the price target from $39 to $13.